Maggie L. Shaw

Primary aldosteronism is often overlooked in hypertension. Educating providers and utilizing tools can enhance screening and treatment effectiveness, emphasizes Vivek Bhalla, MD, Stanford.

The MajesTEC-5 trial shows teclistamab's impressive efficacy in achieving MRD-negative status in newly diagnosed transplant-eligible patients, explains Marc S. Raab, MD, PhD.

Research reveals strong connections between muscle strength and cognitive function in patients with COPD, highlighting the potential for rehabilitation strategies.

Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, explore how understanding MG subtypes and patient characteristics enhances targeted therapy and personalized treatment.

Research exploring protective mechanical ventilation strategies for acute respiratory distress syndrome was presented at the ERS Congress by Luca Menga, MD, University of Toronto.

Michaela Nuttal, MS, explores the complex culture of smoking among nurses, highlighting challenges and motivations for quitting within health care settings.

Nerandomilast for idiopathic pulmonary fibrosis potentially improves survival and slows disease progression, explains Justin Oldham, MD, PhD, MS, FIBRONEER steering committee member.

Emma Guttman, MD, PhD, discusses the promising potential of rocatinlimab in targeting the OX40-OX40 ligand pathway for atopic dermatitis treatment.

Christopher Carlin, MBChB, PhD, explores the potential of AI-driven insights to enhance COPD care and identify candidates for biologic therapy.

Research reveals that a high-fruit diet may protect women's lung function from air pollution, according to Pimpika Kaewsri, MSc.

Integrating these care services can enhance patient QOL and address unmet needs in serious respiratory illnesses, explains Natasha Smallwood, BMedSci, MBBS, MSc, Monash University.

Teclistamab shows promising real-world effectiveness and safety in older adults with relapsed/refractory multiple myeloma (R/R MM), matching clinical trial outcomes.

It's important to enhance MG treatment outcomes with strong provider-patient relationships and ongoing monitoring, explain Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD.

Findings from the ROCKET-SHUTTLE trial reveal the benefits of combining the anti-OX40 monoclonal antibody with topical therapies for atopic dermatitis.

The LINKER-SMM1 trial evaluates linvoseltamab's safety and efficacy in high-risk smoldering multiple myeloma, aiming to delay disease progression.

Research reveals that patients with both rheumatoid arthritis and MASH cirrhosis face significantly higher cardiovascular risks.

Efgartigimod shows promising early response in generalized myasthenia gravis, especially in patients with short disease duration and severe bulbar symptoms.

New findings reveal sotatercept's significant benefits for right ventricular function and tricuspid regurgitation in pulmonary arterial hypertension.

On this episode of Managed Care Cast, experts discuss behavioral health services, stigma reduction, and the 4 dimensions of recovery.

Hearing loss affects mental health, cognition, relationships, and care access, but early intervention and holistic support can improve quality of life.

Research shows that integrating pediatric behavioral health services reduces depression and anxiety symptoms, improving outcomes for children in primary care settings.

More than 2700 parents responded to a survey from the Washington Post and KFF on routine and seasonal childhood vaccinations for their children.

In a recent webinar, experts explored the Most Favored Nation mandate’s implications on drug pricing, patient access, and pharmaceutical innovation.

On July 9, 2025, experts from across Providence Health & Services gathered in Garden Grove, California, for in-depth discussions on patient-centered care for chronic diseases.

Cilta-cel demonstrates superior efficacy and durability in treating high-risk myeloma, balancing effectiveness with safety concerns for patients.

AD-related outcomes were compared in patients treated with JAK1 inhibitors and IL-13 antibodies, with short-term efficacy biomarkers considered for treatment outcomes.

A new FDA-approved blood test for Alzheimer disease could transform diagnosis and treatment accessibility, according to this conversation with Howard Fillit, MD, and Anthony “Nino” Sireci, MD, MSc.

New guidelines and advocacy enhance myasthenia gravis treatment access, promoting proactive management and improved insurance coverage for diverse patient populations.

Discontinuing dupilumab for atopic dermatitis (AD) may increase relapse risk, which requires ongoing management and tailored treatment strategies to manage that risk.

Long-term follow-up data on the use of BCMA-directed RNA chimeric antigen receptor T-cell therapy (CAR T) for refractory generalized myasthenia gravis show patient outcomes at 2, 3, 6, 9, and 12 months.